Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients
August 27, 2021 11:32 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau...
Cassava Sciences Responds to Allegations
August 25, 2021 06:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted...
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
August 24, 2021 08:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the...
Cassava Sciences Reports Second Quarter 2021 Financial Results
August 03, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
August 02, 2021 19:54 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending...
Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
July 29, 2021 09:53 ET
|
Cassava Sciences, Inc.
Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 MonthsRobust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p<...
Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
July 29, 2021 09:53 ET
|
Cassava Sciences, Inc.
Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 MonthsCognition Improved 3.0 Points on ADAS-Cog at 9 Months (p<0.001) Cognitive...
Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
July 26, 2021 08:30 ET
|
Cassava Sciences, Inc.
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam TreatmentSimufilam 100 mg and 50 mg Reduced Plasma Levels of...
Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference
July 21, 2021 08:30 ET
|
Cassava Sciences, Inc.
- On Monday, July 26th, New Clinical Data for SavaDx to be Shared ina Poster Presentation - - On Thursday, July 29th, New Clinical Data for Simufilam to be Featured in a Podium Presentation - ...
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease
June 21, 2021 16:10 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier Research...